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A B S T R A C T
Background: Successfully treated HIV-1 infected patients have a sustained undetectable viral RNA load. In these
cases the total HIV-1 DNA load may constitute a valuable tool to further follow the overall viral burden. The
value of this marker outside of cure research has been rarely studied.
Objectives: To develop a quantitative (q)PCR for total HIV-1 DNA quantification in buffy coat cells and to
evaluate the value of this parameter in clinical follow-up.
Study design: A qPCR using primers and a probe in the conserved HIV-1 LTR region was adapted for use on DNA
extracted from buffy coat cells. Sensitivity, accuracy and reproducibility were evaluated using 8E5 cells and
samples from naive and treatment experienced patients. The clinical value of DNA load analysis was assessed by
testing 119 longitudinal samples from 9 patients before and after ART initiation and 249 cross sectional samples
from therapy-experienced patients.
Results: Inter- and intra-assay coefficients of variability were 5.56 and 5.94 (%CV). HIV-1 DNA was detected in
249 of the 263 (94.7%) patients on ART for at least 5 months (median: 53 months; IQR: 28–84 months). The
HIV-1 DNA load varied between 0.60 and 3.37 copies/106 blood cells and showed significant correlation with
the pre-ART CD4+ T-cell count nadir and peak viral RNA load. ART initiation resulted in a slow and limited
decline of the total HIV-1 DNA concentration.
Conclusions: Quantification of total HIV-1 DNA from buffy coat cells is feasible, sensitive and reliable. Although
determination of the on-therapy HIV-1 DNA load may be informative, regular testing has limited clinical value
because of the very slow evolution.
1. Background
Today, antiretroviral therapy (ART) is initiated immediately after
HIV-1 diagnosis. As a result, most patients have an undetectable HIV-1
RNA load for prolonged periods of time. Quantification of total HIV-1
DNA in peripheral blood mononuclear cells (PBMC) is applied as a
surrogate marker for the size of the HIV reservoir in several HIV cure
studies [1,2]. In patients on ART, the HIV-1 DNA load may reflect the
overall viral burden and therefore constitute a potentially interesting
marker for clinical follow-up. A number of studies suggest that the HIV-
1 DNA load may guide the selection of patients eligible for ART de-
escalation. In the VISCONTI cohort, low HIV-1 DNA levels were cor-
related with better control of the virus after therapy cessation [3] and in
other studies a correlation between HIV-1 DNA levels and post-treat-
ment control was demonstrated [4,5]. But there are also reports of
immediate viral rebound upon treatment interruption even in patients
with undetectable HIV-1 DNA levels [6,7].
In untreated patients, association of the HIV-1 DNA load with the
HIV-1 RNA load and with the number of CD4+ T-cells, has been clearly
demonstrated [6,8–14]. Others have shown that the total HIV-1 DNA
load in the first 24 months after infection can predict progression to
AIDS independent of the HIV-1 RNA load or CD4+ T-cell count
[5,15–17].
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The purpose of this study was to evaluate the feasibility and added
value of total HIV-1 DNA load measurement in routine laboratory
monitoring of HIV-1 infected patients. To avoid cumbersome PBMC
isolation, the possibility to use stored EDTA blood buffy coat cells for
HIV-1 DNA quantification was examined. HIV-1 DNA quantification
was performed using the real-time qPCR developed by Avettand-Fènoël
et al. [18]. After ensuring the feasibility and reliability of the method, it
was validated using large series of samples from patients on ART. The
DNA load range and evolution over time, and the parameters associated
with a high or low total HIV-1 DNA load were assessed.
3. Study design
3.1. Sample series used for assay validation
DNA extracted from HIV-1 LAV infected 8E5 cells [20] was spiked
in 600 ng/ml HIV negative human DNA (Roche, Basel, Switzerland) to
construct a titration curve. Test variability was defined after triplicate
testing, both inter- and intra-assay, of 15 samples collected from
therapy-experienced patients and selected to cover a broad HIV-1 DNA
load range (0.60 and 3.20 c/106 cells).
3.2. Sample series used to define the added clinical value of DNA load
analysis
In total, 119 consecutive samples were retrospectively selected from
9 patients (between 7 and 17 samples per patient). They were collected
pre- and post-ART over a period of 69–87 months. The median age of
the patients at diagnosis was 34 years (IQR: 32–37 years), 7 of them
were men of which at least 5 were MSM (men who have sex with men),
7 were Belgians and 2 were Africans. Median pre-ART CD4+ T-cell
count nadir and peak viral load were 327 cells/mm3 (IQR: 283–434
cells/mm3) and 4.99 log copies/ml (c/ml) (IQR: 4.58–5.56 log c/ml)
respectively.
Cross-sectional samples were retrospectively selected from 249 pa-
tients on ART. For inclusion, patients needed to have an undetectable
viral load (< 20 c/ml) for at least 3 months though isolated viral blips
(IQR: 58–183 c/ml; 26.1% of the patients) were accepted. The median
age of the selected patients was 43 years (IQR: 37–52 years), 80.3%
were men of which 70.0% were MSM, 68.7% were Belgians and 19.7%
were Africans. The median time between diagnosis and sample collec-
tion was 72 months (IQR: 42–116 months), the median on-ART time
was 53 months (IQR: 28–84 months) and the median time of un-
detectable viral load was 47 months (IQR: 24–79 months). Median pre-
ART CD4+ T-cell count nadir and peak viral load were 254 cells/mm3
(IQR: 166–341 cells/mm3) and 4.9 log c/ml (IQR: 4.5–5.4 log c/ml)
respectively.
All patients providing the included samples were followed at Ghent
University Hospital, Ghent, Belgium.
3.3. Blood collection and sample preparation
Venous blood, collected in EDTA containing collection devices, was
centrifuged at 1900 g for 10min within 24 h of collection. After removal
of the plasma for viral load analysis, about 750 μl of the upper cell layer
(buffy coat) was transferred to a clean vial for storage at −80 °C.
At the time of initiating the qPCR analysis, the buffy coats were
thawed and 200 μl was subjected to DNA extraction using the QIAamp
Blood Kit (Qiagen, Hilden, Germany) following the manufacturer’s in-
structions. This extraction can be fully automated using the QIAcube
(Qiagen). The resulting DNA, eluted in 200 μl elution buffer, was then
concentrated in 50 μl ultrapure water by ethanol precipitation.
3.4. HIV-1 DNA load determination
Part of the HIV-1 LTR was amplified using the primers and probe
described by Avettand-Fènoël et al. [18], the QuantiTect multiplex PCR
kit (Qiagen) and the LightCycler480 (Roche, Basel, Switzerland). For
normalization, part of the human albumin (ALB) gene was amplified in
parallel using primers and probe described by Gault et al. [19]. All
qPCR reactions were performed in a 50 μl reaction volume containing
20 μl DNA extract, 200 nM of each primer and probe and 1x Quantitect
multiplex mastermix for the HIV PCR and 2 μl DNA extract, 100 nM of
each primer, 150 nM of the probe and 1x Quantitect multiplex mas-
termix for the human ALB PCR. Thermocycling conditions were 2min
at 50 °C and 10min at 95 °C, followed by 45 cycles at 95 °C for 15 s and
60 °C for 1min and a final cool down to 37 °C for 3min. Each run in-
cluded 3 replicates of a low positive control (LPC), containing 600 ng/μl
human genomic DNA (Roche) spiked with DNA from 20 8E5 cells [20].
For all runs performed, the average ALB Cq value of the LPC replicates
fell within the two standard deviation (SD) boundaries that were pre-
defined based on 11 independent measurements of the LPC. Normal-
ization of the HIV-1 DNA load to the white blood cell number was done
using the Cq values of ALB and the 2−ΔΔCt method developed by Livak
and Schmittgen [21]. The LPC contained 20 copies HIV-1 DNA from
8E5 cells per reaction. The total DNA concentration per reaction mea-
sured by NanoDrop™(Thermo Fisher Scientific, Waltham, MA) was 4 μg.
Assuming that 1 μg of DNA is equivalent to ∼150,000 cells [18,22], the




Groups were compared using χ2 test for categorical variables and
Mann-Whitney U non parametric test for continuous variables. The
level of significance was set at p≤ 0.05. All data was analyzed using
SPSS23.0 (SPSSInc., Chicago, IL).
4. Results
4.1. Method validation
Six dilutions of HIV-1 LAV infected 8E5 cells (0, 10, 20, 100, 500
and 2000 HIV DNA copies/reaction) spiked in 600 ng/μl negative
human DNA, were tested in three independent runs. The average and
standard deviation for each dilution was calculated and the titration
curve constructed (Supplementary Fig. 1).
Fifteen cross-sectional samples, with an HIV-1 DNA load evenly
distributed across a broad range (0.60 and 3.20 c/106 cells), were tested
to define inter- and intra-assay reproducibility. The coefficients of
variance for 3 independent measurements were 5.94 (intra-run) and
5.56 (inter-run) (Table 1). The Cq values for ALB varied between 16.17
and 20.89.
4.2. HIV-1 DNA load pre- and post-ART
HIV-1 DNA was quantifiable in 119 (96.0%) of 124 samples col-
lected longitudinally from 9 patients before and after ART initiation
(Fig. 1). The median ALB Cq value for these samples was 17.57 (IQR:
16.80–18.45). For two samples neither HIV-1 DNA nor ALB DNA were
detected (Cq>40). For three samples the HIV-1 DNA load did not
reach the limit of quantification (Cq ≥ 35), likely due to the low
amount of DNA present, with ALB Cq values of respectively 19.22,
21.53 and 24.06 reducing the detection limit for HIV-1 DNA to re-
spectively 0.93, 1.63 and 2.39 log c/106 cells. The results of the two
samples with undetectable and the three samples with unquantifiable
HIV-1 DNA were not taken into account in Fig. 1.
The overall per patient fluctuations in pre-ART HIV-1 DNA load
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varied a maximum of 1.61 log c/106 cells (median: 0.50 log c/106
cells). After treatment initiation the per patient DNA load dropped from
a median of 2.95 log c/106 cells to a median of 2.16 log c/106 cells.
Overall, the median difference between the highest pre- and lowest on-
ART DNA load was 1.16 log c/106 cells (minimum 0.67 log c/106 cells,
maximum 1.64 log c/106 cells).
4.3. HIV-1 DNA load after long-term ART
HIV-1 DNA quantification was successful for 94.7% of the 263 cross-
Table 1
Calculation of the intra- and inter-assay coefficient of variation after triplicate testing of 15 cross-sectional samples, selected to cover a broad linear range of HIV-1
DNA loads. Differences in the Cq values for ALB reflect the variability in cell content of the buffy coats.
Intra-assay variability Inter-assay variability
ALB HIV-1 DNA SD %CV ALB HIV-1 DNA SD %CV
(Mean Cq) (Mean log c/106 cells) (Mean Cq) (Mean log c/106 cells)
sample 1 16.17 0.73 0.23 31.45 16.31 0.54 0.10 18.48
sample 2 17.23 1.40 0.03 1.94 17.36 1.43 0 0.32
sample 3 17.68 1.49 0.05 3.30 17.81 1.55 0.10 6.21
sample 4 17.90 1.42 0.34 24.36 17.92 1.39 0.31 22.48
sample 5 16.52 1.72 0.03 1.67 16.49 1.65 0.07 4.01
sample 6 18.26 1.73 0.10 5.97 18.24 1.74 0.05 2.61
sample 7 18.63 1.92 0.05 2.49 18.59 1.92 0.03 1.74
sample 8 18.21 2.02 0.06 2.91 18.01 1.96 0.16 8.03
sample 9 16.65 2.16 0.01 0.43 16.74 2.21 0.04 1.85
sample 10 17.17 2.05 0.02 0.74 16.95 1.95 0.10 5.29
sample 11 17.76 2.06 0.07 3.36 17.76 2.11 0.03 1.59
sample 12 16.92 2.24 0.08 3.56 16.95 2.22 0.03 1.41
sample 13 19.33 2.15 0.06 2.85 19.23 2.07 0.13 6.40
sample 14 18.49 2.56 0.05 2.06 18.26 2.57 0.03 1.33
sample 15 20.89 2.74 0.05 1.93 20.83 2.69 0.04 1.58
intra-assay %CV: 5.94 inter-assay %CV: 5.56
Fig. 1. Evolution of the HIV-1 DNA load (log c/106 cells) and HIV-1 RNA load (log c/ml plasma) over time in 9 patients. Gray dotted line: ART initiation.
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sectional samples collected from 263 patients on long-term ART. The
median Cq value for ALB was 18.60 (IQR: 17.66–19.83). The median
total HIV-1 DNA load registered was 2.18 log c/106 cells (IQR
1.84–2.40 log c/106 cells). The maximum range of inter-patient varia-
tion was 2.77 log c/106 cells.
Patients were then divided in two groups, patients with a DNA load
above the overall median DNA load of 2.18 log c/106 cells (123 pa-
tients) and patients with a DNA load below or equalizing this median
(126 patients) in order to define potential correlates for high or low
HIV-1 DNA load (Table 2). A pre-ART CD4+ T-cell count nadir below
200 cells/mm3 and a pre-ART peak viral load above 5 log c/ml were
significantly associated with a higher HIV-1 DNA load (p= 0.011 and
p=0.034 respectively). Patients experiencing viral blips were also
more likely to have higher DNA loads but this association was not
statistically significant (Table 2). The same analysis comparing patients
with a HIV-1 DNA load in the upper quartile range with the patients
with a HIV-1 DNA load in the lower quartile range resulted in a similar
outcome (data not shown).
5. Discussion
Quantification of total HIV-1 DNA in blood cells or body compart-
ments is frequently applied in HIV reservoir and cure research
[2,23–26] but the potential of this marker for routine clinical mon-
itoring remains virtually unexplored. The vast majority of HIV-1 in-
fected patients are successfully treated, resulting in an undetectable
viral load for extended periods of time. Thus, having a marker that
permits to further monitor the overall viral burden looks interesting,
especially in the light of increasing interest in the possibilities to
downscale or even interrupt treatment [1,4,27–35]. Of all the reservoir
markers proposed, the total HIV-1 DNA load is definitely the most easily
accessible for broad scale screening and there are several indications for
a potential value in routine practice. It has been demonstrated that
patients with the ability to suppress virus replication naturally have
lower HIV-1 DNA levels than control patients [36–38] and, more im-
portantly, patients with a low HIV-1 DNA load are more likely to evolve
to functional cure than patients with an extended reservoir [39,40].
Broad scale screening of the viral DNA load may therefore enable
identification of patients with the highest chance of benefitting from
treatment de-escalation or cessation.
One of the reasons why HIV-1 DNA load measurement remains
largely restricted to research environments may be that the analysis is
technically challenging and commercial kits specifically developed for
this purpose are unavailable. The HIV-1 DNA quantification protocols
described in literature generally use DNA extracted from purified PBMC
and some even recommend isolation of the CD4+ T-cell population
[6,10,26,41]. These procedures are cumbersome and difficult to im-
plement in routine laboratory practice. The aim of this study was to
establish a method for HIV-1 DNA quantification that can easily be
implemented in a routine clinical laboratory. The buffy coat cell frac-
tion is the upper cell layer of EDTA blood after centrifugation and can
easily be recuperated and stored. We used a manual DNA extraction
procedure from the company Qiagen that can easily be automated, but
alternative DNA extraction procedures can be applied as well, enabling
the easy integration of both collection and processing in a routine
clinical lab. An additional ethanol precipitation step was introduced to
increase the sensitivity of the HIV-1 DNA quantification by concentra-
tion of the extracted DNA, but this step is optional.
To our knowledge the use of whole blood for HIV-1 DNA quantifi-
cation was only mentioned by Casabianca et al. [42] and Avettand-
Fènoël et al. [18]. Though Avettand-Fènoël et al. [18] used purified
PBMCs for most of their work, they did compare DNA quantification in
ficoll-hypaque separated PBMC with DNA quantification in whole blood
for 48 samples and found a very good correlation (Spearman test
r= 0.900, p < 0.0001). One of the difficulties when using whole
blood or buffy coat cells is defining the number of white blood cells in
the cell fraction, necessary for normalization of the results. This pro-
blem was solved by introducing the ALB qPCR described by Gault et al.
[19]. The concentration of human ALB gene DNA is used as a measure
for total genomic DNA content and the total genomic DNA content as a
measure for cell count. An alternative is to quantify the extracted DNA
by NanoDrop spectrophotometry prior to real-time PCR and to report
the HIV-1 DNA load as c/μg DNA as proposed by Casabianca et al. [43].
HIV-1 DNA was detectable and quantifiable in 94.7% of cross sec-
tional buffy coat samples from 263 patients with undetectable viral
load, confirming the high sensitivity of the assay. Moreover, the ob-
tained HIV-1 DNA copy numbers closely resembled DNA loads reported
for comparable populations [9,14,18]. Our selection of on-ART patients
represented a very heterogeneous group with regard to the duration of
infection before ART initiation, the on-ART period, pre-treatment viral
load and CD4 count. Despite this heterogeneity, the range of HIV-1 DNA
Table 2









n= 249 n=123 n=126 P
Sex, n (%), 249 (100) 123 126 0.307
Man 200 (80.3) 102 (82.9) 98 (77.8)
Woman 49 (19.7) 21 (17.1) 28 (22.2)
Age, median (IQR),
years, (n= 249)
43 (37–52) 43 (37–52) 44 (37–52) 0.693
Infection route, n (%) 197 (79.1) 104 93 0.940
MSM 140 (71.1) 75 (72.1) 65 (69.9)
HE 43 (21.8) 22 (21.2) 21 (22.6)




72 (42–116) 64 (42–103) 86 (40–127) 0.112
Time on ART, median
(IQR), months,
(n=249)
53 (28–84) 53 (29–83) 53 (28–89) 0.807









CD4+ cell count nadir,
< 200 cells/mm3,
n (%)
248 (99.6) 123 125 0.011
Yes 90 (36.3) 35 (28.5) 55 (44.0)
No 158 (63.7) 88 (71.5) 70 (56.0)
Peak VL, median (IQR),






Peak VL, > 5 log c/ml,
n (%)
249 (100) 123 126 0.034
Yes 114 (45.8) 48 (39.0) 66 (52.4)
No 135 (54.2) 75 (61.0) 60 (47.6)
Viral load rebound (c/
ml), n (%)
249 (100) 123 126 0.054
<50 180 (72.3) 96 (78.0) 84 (66.7)
50-200 47 (18.9) 22 (17.9) 25 (19.8)
201-1000 15 (6.0) 3 (2.4) 12 (9.5)
> 1000 7 (2.8) 2 (1.6) 5 (4.0)
Viral load rebound, n
(%)
249 (100) 123 126 0.058
Yes 183 (73.5) 97 (78.9) 86 (68.3)





47 (24–79) 47 (27–71) 47 (23–84) 0.748
Origin, n (%) 249 (100) 123 126 0.518
Belgium 171 (68.7) 91 (74) 80 (63.5)
Europe 12 (4.8) 5 (4.1) 7 (5.6)
Africa 49 (19.7) 20 (16.3) 29 (23.0)
America 7 (2.8) 3 (2.4) 4 (3.2)
Asia 10 (4.0) 4 (3.3) 6 (4.8)
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concentrations remained limited, varying between 0.60 and 3.37 log c/
106 cells (IQR of 1.84 to 2.40 log c/106 cells). Because the majority of
these samples were collected more than a year after ART initiation, the
measured viral DNA concentration most probably reflects the long-term
persistent latent reservoir and it is known that this reservoir is small
and very stable [44–46]. Interestingly, although these samples were
collected a long time after ART initiation, pretreatment viral load and
pretreatment CD4+ T-cell count remained significantly predictive for
the on-ART HIV-1 DNA load. Burgard et al. [9] and Fourati et al. [13]
came to the same conclusions using PBMCs for DNA load analysis.
Other groups only observed a correlation between the HIV-1 DNA load
and the CD4+ T-cell count nadir [10] or between the HIV-1 DNA load
and pre-ART viral load [14].
The variation in HIV-1 DNA load over time is much lower than the
variation of the viral RNA load, as illustrated for the 9 patients followed
longitudinally. The overall difference in median pre-ART DNA load and
median on-ART DNA load did not exceed 1 log c/106 cells. In com-
parison, the drop in RNA load for the same samples varied between
2.88 and 6.52 log c/ml. Re et al. [47] analyzed the evolution of the HIV-
1 DNA load in PBMC cells of 19 ART-naive patients. They found no
appreciable difference in DNA load between two samples collected with
an interval of 12 months (median 2.86 log c/105 PBMC for the first
sample versus 2.72 log c/105 PBMC for the second sample; p > 0.1). In
treated patients, the HIV-1 DNA load decreased significantly but with
limited magnitude, not exceeding 1 log c/105 PBMC [47]. A similar
observation was made by Koelsch et al. [48] who reported median rates
of decay between 0.25 and 1.03 log c/μg total DNA. All these ob-
servations question the value of frequent DNA load determination.
The results of the longitudinal follow-up samples revealed some
unexpected fluctuations in HIV-1 DNA load probably reflecting the
biological variability although technical errors due to founder effects
during sample collection and DNA extraction that are inherent to this
type of analyses on low input material cannot be excluded. Overall
however, the inter- and intra-run coefficients of variance remained low
indicating that the qPCR error rate is limited. High inter-laboratory
reproducibility of the HIV-1 DNA load measurement has also been re-
ported by Désiré et al. [49], De Rossi et al. [50], Avettand-Fènoël et al.
[1] and Gantner et al. [51].
Apart from the fact that the inter-patient viral DNA load range is
limited and that the evolution over time of the DNA load is slow, recent
findings also revealed that the vast majority of HIV-1 DNA in blood cells
is defective [52–54]. This may further impact the potential value of
DNA load assessment. The likeliness that the ratio of defective over
replication competent viral DNA is comparable between patients
[52,53] however may somewhat refute the last criticism.
Our results show that the curve of the DNA load before and during
ART overall follows a similar course in different patients and that small
differences in this curve are largely determined by pre-ART conditions
reflected in the CD4 nadir and peak viral load. This suggests that reg-
ular follow-up of the DNA load has limited added value. Determination
of the baseline DNA load at treatment initiation and assessment of the
set point HIV-1 DNA load at a specific time point afterwards, however,
may be appropriate (as suggested by Maurizio Zazzi – oral presentation
‘The clinical use of HIV-DNA quantity and resistance testing’, 15th
European Meeting on HIV & Hepatitis Treatment Strategies & Antiviral
Drug Resistance, 7–9 June 2017, Rome, Italy).
Additionally, for patients for whom historic lab results are missing,
the HIV DNA load measured during ART may provide some indications
on the pre-ART stage.
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